World Biosimilar Congress USA 2022 is dedicated to common barriers in accessing the US biosimilars market, including time-consuming R&D, high development costs and lengthy clinical trials.
Topics
- How can we increase understanding of biosimilars among physicians, patients, and other key stakeholders?
- What are the myths and realities about biosimilars?
- Determining risk of anaphylaxis, autoimmunity, and anti-drug antibodies
- Why do biosimilars require a paradigm shift in our approach to evaluating clinical data?
- Exploring the utility of models in the science of comparison in the context of difficult challenges in biosimilar development
- Assessing impact of subtle recognized differences in quality attributes extrapolated over time, and across a heterogeneous population
Who should Attend
Senior attendees from the bio-pharmaceutical industry.
